Incyte (INCY) Misses Q2 EPS by 3c, Sales Beat; Raises FY17 Jakafi Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs
August 1, 2017 7:00 AM EDT$276 million of 2017 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 33 percent growth over the same period last year Proof-of-concept data for the combination of epacadostat plus PD-1 inhibition presented at the American Society of Clinical Oncology Annual Meeting (ASCO) 2017 across multiple tumor types; expanded Phase 3 program on track for planned initiation in 2017 Multiple product candidates in late-stage clinical development illustrates transformational growth potential of Incytes portfolio
Conference Call and Webcast Scheduled Today at 10:00 a.m. ET
WILMINGTON, Del.--(BUSINESS... More
